Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant streptokinase
- Development stage
- Phase 4
- Lead developer
- Bharat Biotech
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous, Intra-arterial
01
Overview
Recombinant streptokinase is a thrombolytic agent derived from *Escherichia coli* using recombinant DNA technology. It is used to dissolve blood clots in conditions such as myocardial infarction, pulmonary embolism, and deep vein thrombosis. It works by activating the fibrinolytic system, converting plasminogen to plasmin, which then breaks down fibrin clots[4][5].
- Brand names
- MYOKINASE
- Other names
- rSK
02
Targets
PLG (Plasminogen)
Beyond the preview
Go deeper on recombinant streptokinase.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant streptokinase.